PharmTech News

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

Articles

The move follows a warning from FDA wherein FDA cited ALK-Abello with numerous manufacturing violations.

Merck Returns Rights to Allergy Tablets Back to ALK-Abello

The Phase I trial will test Bavarian Nordic’s vaccine, which is manufactured using a vaccine vector based on smallpox.The recent resurgence of yellow fever incidences over the past six months has prompted health officials to ramp up the fight against the virus. Like the Zika virus, yellow fever is transmitted primarily through the bite of infected female Aedes aegypti mosquitoes.

NIH-Backed Yellow Fever Vaccine Trial Announced

On July 27, 2016, John C. Lechleiter, PhD, chairman, president, and CEO of Eli Lilly, announced his retirement from the company. This decision is effective December 31, 2016, however, Lechleiter will remain on the company’s board of directors until May 31, 2017 as a non-executive chairman. Lechleiter joined the company in 1979 as a senior organic chemist in process R&D. He has served as CEO of Eli Lilly since April 2008.

Eli Lilly CEO Announces Retirement

The vaccine candidate has also won a Priority Medicines (PRIME) status from EMA.

Merck Receives Breakthrough Therapy Designation for Ebola Vaccine

Amgen and Allergan’s biosimilar to popular breast cancer drug Herceptin is comparable to the innovator molecule, Amgen recently announced.

No Clinically Meaningful Differences Between Herceptin and Amgen/Allergan Biosimilar

A new website collects and rates information about life-science supplies from academic journals to simplify researcher purchasing decisions.

Open-Access Technology Seeks to Make Drug Discovery Easier

Thirty percent of current Remicade patients could be eligible for a switch to competitors such as Inflectra, according to estimates, although J&J doubts this will occur in the United States in 2016.

Will Biosimilars to Remicade Capture Market Share in 2016?

On July 19, 2016, Pfizer announced that the World Health Organization (WHO) has prequalified its four-dose, multi-dose vial (MDV) presentation of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13 – valent, adsorbed]). According to the company, WHO prequalification allows for the global use of Prevenar 13 MDV by the United Nations agencies and countries worldwide that require WHO prequalification.The MDV presentation of Prevenar 13 offers benefits to developing countries, including a 75% reduction in:

Pfizer Receives Prequalification for Presentation of Prevenar 13

EAG Laboratories announces new company identity and intent to expand testing, analysis, and characterization capabilities across multiple markets.

EAG Inc. Rebrands Businesses, Including ABC Labs, as EAG Laboratories

Patheon launches initial public offering to repay outstanding notes and expenses.

Top News